Why Is BELITE BIO INC ADR (BLTE) Stock Up Today?

BLTE stock surged 12.22% to $192.00 in early trading on Friday, driven by a series of analyst upgrades and renewed investor interest in the biotech firm’s Stargardt therapy pipeline. The stock opened with a 1.6% gap up and reached an intraday high of $193.57 before settling near $191.55. Coverage from multiple analysts and a strong intraday volume of 0.4M shares contributed to the sharp rise.

What Happened

Canaccord initiated coverage of Belite Bio with a Buy rating, citing the company’s Stargardt therapy as a key growth driver. The firm also set a price target of $303. H.C. Wainwright reiterates its positive stance on the company’s commercial plans, reinforcing the bullish sentiment. These analyst actions came alongside a broader market focus on biotech innovation and post-IPO momentum. The stock’s price action reflected this optimism, with a strong intraday rally that pushed it closer to its 52-week high of $200.00.

What The Data Shows

The stock opened at $173.83 and traded as low as $171.00 at the market open before climbing steadily. Volume reached 0.4M shares, which is 2.1 times the 3-month daily average, indicating heightened institutional or retail participation. The stock has traded in a 52-week range of $63.51 to $200.00 and has a market capitalization of $6.5 billion. Despite a recent EPS of -2.74 for the trailing twelve months, the stock’s fundamentals are being reevaluated in light of the analyst upgrades.

What To Watch

With the stock near its 52-week high and multiple analyst firms expressing confidence in its commercial prospects, the next key event will be the company’s upcoming earnings report. Investors should also monitor coverage breadth and whether additional analysts join the bullish consensus.